Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2017

View Archived Issues

Mitsubishi Tanabe Pharma offers overview of first quarter of fiscal 2017

Pfizer reflects on milestones of second quarter 2017

MiMedx initiates phase III study of AmnioFix Injectable following phase IIb results

Pellficure Pharmaceuticals begins enrollment in phase I trial of PCUR-101 in metastatic CRPR

Proclara Biosciences' GAIM-Ig fusion NPT-189 blocks assembly of amyloid aggregates

Intec reports phase I results for AP-CBD/THC

Vaccibody files German clinical trial application for cancer neoantigen vaccine VB10.NEO

FDA approves Mavyret for HCV

Cormedix provides update on ongoing phase III study of Neutrolin

Novel peptide-based viral inactivator shows promise as treatment against ZIKV in vivo

EMA announces business continuity plan to prepare for U.K.'s withdrawal from the E.U.

Sentinel Oncology receives Innovate UK grant to study SOL-784

Bristol-Myers Squibb to acquire IFM Therapeutics

FDA advisory committee recommends approval of Xeljanz for psoriatic arthritis

ANGPTL3 antagonism is associated with reduced risk of atherosclerotic cardiovascular disease

Takeda and Molecular Templates establish new oncology drug discovery collaboration

Novel susceptibility variants for Alzheimer's disease identified in Chinese subjects

Realm Therapeutics submits IND for PR-013 for allergic conjunctivitis

EpiVax receives funding to support development of personalized cancer vaccines

Oxeia acquires rights to SUN-11031 from KineMed

FDA approves Vyxeos for two types of AML

U.S. researchers patent antiparasitic compounds

Beth Israel Deaconess Medical Center discloses CRAC blockers

Janssen Pharmaceutica identifies MAP3K14 inhibitors

Sichuan Haisco Pharmaceutical divulges new antivirals

NIH researchers develop mouse model to track Zika virus transmission

Dolutegravir superior in combination with NRTIs for treating HIV-1 infection

FDA awards orphan drug designation to Applied Genetic Technologies' gene therapy candidate for XLRP

Portola resubmits AndexXa BLA

Dynavax updates status of Heplisav-B submission following FDA advisory committee meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...